Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.

doi:10.1016/j.eururo.2024.06.018

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.

European urology - 1 Oct 2024

Plimack Elizabeth R, Tangen Catherine, Plets Melissa, Kokate Rutika, Xiu Joanne, Nabhan Chadi, Ross Eric A, Grundy Erin, Choi Woonyoung, Dinney Colin P N, Lee I-Ling C, Fong Megan, Scott Lucia M, Daneshmand Siamak, Theodorescu Dan, Goldkorn Amir, Lerner Seth P, Flaig Thomas W, McConkey David J

Abstract excerpt

We previously reported that tumors harboring any one of four gene mutations (ATM, RB1, FANCC, or ERCC2) were likely to respond to neoadjuvant cisplatin-based chemotherapy (NAC), resulting in cancer-free surgical specimens at the time of cystectomy (pT0). Here, we report our validation of this finding. Using the CARIS 592 Gene Panel (Caris Life Sciences, Phoenix, AZ, USA), we analyzed 105 pre-NAC tumor specimens...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Cisplatin

Share to Neoadjuvant Therapy

Share to Neoplasm Invasiveness

Share to Retinoblastoma Binding Proteins

Share to Urinary Bladder Neoplasms

Share to Xeroderma Pigmentosum Group D Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 39003201
DOI: 10.1016/j.eururo.2024.06.018
PMCID: PMC11416320

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.PMID 39003201Read ↗

Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerSemantic proximity Read ↗

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.Semantic proximity Read ↗

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).Semantic proximity Read ↗

Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder CancerSemantic proximity Read ↗

Resistance to Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: Genetic and Immune Determinants and Implications for Treatment Sequencing — A Case SeriesSemantic proximity Read ↗

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.Semantic proximity Read ↗

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.Semantic proximity Read ↗

Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.Semantic proximity Read ↗

Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene AssessmentSemantic proximity Read ↗

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.Semantic proximity Read ↗

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.